This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: redirect Compound OTHER HIGH

Rhodiola Rosea 3:1

Extended Research
Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict OTHER HIGH

This is the same compound as rhodiola.md. The "3:1" notation refers to a herb-to-extract concentration ratio (3 g raw root yields 1 g extract) that does NOT specify rosavin or salidroside content. For meaningful pharmacology, prefer SHR-5 or rosavin-standardized extracts. See parent file rhodiola.md for full analysis.

Research pass: redirect
Cross-references

For full mechanism, dosing, evidence, side effects, sourcing, decision matrix, and this-archetype verdict, see:

  • rhodiola.md — canonical Rhodiola rosea entry, CONFIRMED-IN-USE in V4 at Nature's Way 250 mg/day

References

Panossian et al. 2010 — Rhodiola rosea standardization review (Phytomedicine)

pubmed.ncbi.nlm.nih.gov · 2010
View Study

Booker et al. 2016 — quality variability across rhodiola products (J Ethnopharmacol)

pubmed.ncbi.nlm.nih.gov · 2016
View Study

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…